Shanghai Euregen Biopharma

Shanghai Euregen Biopharma (now Zhongshan Youli Biopharma) is a preclinical-stage biopharmaceutical company focused on developing next-generation "synthetic lethal" (Synthetic Lethality 2.0) therapies for cancers driven by the deletion of tumor suppressor genes. Founded in 2021 by Dr. Xuxing Chen, the company leverages its expertise in medicinal chemistry to target key oncogenic pathways, particularly in MTAP-deleted cancers. Its pipeline includes EB-160, a highly potent and brain-penetrant KRAS G12C covalent inhibitor currently in the IND application stage, alongside preclinical programs targeting MAT2A, PRMT5, Menin, and PARP7. Euregen operates through its subsidiary Suzhou Youli Biomedical Technology and is backed by investors such as Fuhuo Capital.